Mechanistically, the oncogenic action of DSCAM-AS1 was demonstrated to interact with nuclear ribonucleoprotein hnRNPL in breast cancer cells, which has been found to facilitate progression of breast cancer and induce resistance to tamoxifen [14]. This evidence concerns the gene DSCAM-AS1 and breast carcinoma.